EP0547149A4 - Inhibition of herpesviridae infection by antisense oligonucleotides - Google Patents

Inhibition of herpesviridae infection by antisense oligonucleotides

Info

Publication number
EP0547149A4
EP0547149A4 EP19910916956 EP91916956A EP0547149A4 EP 0547149 A4 EP0547149 A4 EP 0547149A4 EP 19910916956 EP19910916956 EP 19910916956 EP 91916956 A EP91916956 A EP 91916956A EP 0547149 A4 EP0547149 A4 EP 0547149A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
antisense oligonucleotides
herpesviridae infection
herpesviridae
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910916956
Other languages
English (en)
Other versions
EP0547149A1 (fr
Inventor
Bernard Roizman
Kameron W. Maxwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genta Inc
Original Assignee
Genta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genta Inc filed Critical Genta Inc
Publication of EP0547149A1 publication Critical patent/EP0547149A1/fr
Publication of EP0547149A4 publication Critical patent/EP0547149A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
EP19910916956 1990-08-15 1991-08-13 Inhibition of herpesviridae infection by antisense oligonucleotides Withdrawn EP0547149A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56850190A 1990-08-15 1990-08-15
US568501 1990-08-15

Publications (2)

Publication Number Publication Date
EP0547149A1 EP0547149A1 (fr) 1993-06-23
EP0547149A4 true EP0547149A4 (en) 1993-09-01

Family

ID=24271562

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910916956 Withdrawn EP0547149A4 (en) 1990-08-15 1991-08-13 Inhibition of herpesviridae infection by antisense oligonucleotides

Country Status (10)

Country Link
EP (1) EP0547149A4 (fr)
JP (1) JPH06500469A (fr)
KR (1) KR930701105A (fr)
AU (2) AU8617691A (fr)
CA (1) CA2089476A1 (fr)
IE (1) IE912883A1 (fr)
IL (1) IL99172A (fr)
NZ (1) NZ239372A (fr)
TW (1) TW226408B (fr)
WO (1) WO1992003051A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105595A1 (fr) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Polynucleotides antisens
ATE188479T1 (de) 1994-06-01 2000-01-15 Hybridon Inc Verzweigte oligonukleotide als pathogenhemmende mittel
WO1996013608A2 (fr) * 1994-10-28 1996-05-09 Innogenetics N.V. Sequences d'acide polynucleique utilisees dans la detection et la differenciation d'organismes procaryotes
CA2223032A1 (fr) * 1997-02-21 1998-08-21 Smithkline Beecham Corporation Utilisation de ul-15 et de vp5 du hsv-1 pour la detection d'agents antiviraux
KR101360955B1 (ko) 2002-09-13 2014-02-10 레플리코르 인코포레이티드 비서열 상보적 항바이러스 올리고뉴클레오티드

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148302A (en) * 1983-10-17 1985-05-30 Akira Kaji Method for inhibiting viral propagation and anti-viral agent
WO1991012811A1 (fr) * 1990-02-26 1991-09-05 Isis Pharmaceuticals, Inc. Therapies utilisant des oligonucleotides pour moduler les effets d'herpesvirus
WO1992005284A1 (fr) * 1990-09-21 1992-04-02 University Of Maryland Compositions et procedes inhibant la croissance ou la replication de virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148302A (en) * 1983-10-17 1985-05-30 Akira Kaji Method for inhibiting viral propagation and anti-viral agent
WO1991012811A1 (fr) * 1990-02-26 1991-09-05 Isis Pharmaceuticals, Inc. Therapies utilisant des oligonucleotides pour moduler les effets d'herpesvirus
WO1992005284A1 (fr) * 1990-09-21 1992-04-02 University Of Maryland Compositions et procedes inhibant la croissance ou la replication de virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF BIOLOGICAL CHEMISTRY vol. 264, no. 19, 5 July 1989, BALTIMORE, MD US pages 11521 - 11526 GAO, W. ET AL. 'EFFECT OF PHOSPHOROTHIOATE HOMO- OLIGODEOXYNUCLEOTIDES ON HERPES SIMPLEX VIRUS TYPE 2-INDUCED DNA POLYMERASE' *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 83, May 1986, WASHINGTON US pages 2787 - 2791 SMITH, C.C. ET AL. 'Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5' *

Also Published As

Publication number Publication date
WO1992003051A1 (fr) 1992-03-05
NZ239372A (en) 1997-06-24
KR930701105A (ko) 1993-06-11
AU8617691A (en) 1992-03-17
AU3776395A (en) 1996-02-29
IL99172A (en) 1999-03-12
JPH06500469A (ja) 1994-01-20
EP0547149A1 (fr) 1993-06-23
IE912883A1 (en) 1992-02-26
IL99172A0 (en) 1992-07-15
TW226408B (fr) 1994-07-11
CA2089476A1 (fr) 1992-02-16

Similar Documents

Publication Publication Date Title
HU9402822D0 (en) Antisense oligonucleotide inhibition of papillomavirus
EP0759979A4 (fr) Inhibition par oligonucleotides antisens du virus de l'hepatite c
IL108367A0 (en) Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
GB2280606B (en) Physical forms of benzenesulphonamides
FI960374A0 (fi) Verisuoniendoteelikasvutekijän ilmestymisen estäminen antisenseoligonukleotideilla
HU9300364D0 (en) Inhibition of ann arbor h2n2 breed of influence a-type virus with complementeric oligonucleotides
GB9016973D0 (en) Viral growth inhibition
ZA906621B (en) Use of viruses against undesirable micro-organisms
EP1009860A4 (fr) Inhibition du gene ras a l'aide d'oligonucleotides antisens
GB9021672D0 (en) Inhibition of scale
ITRM910890A0 (it) Nuovi oligonucleotidi antisenso
EP0547149A4 (en) Inhibition of herpesviridae infection by antisense oligonucleotides
HU9500979D0 (en) Antisense oligonucleotide inhibition of the ras gene
ZA917739B (en) Scale inhibition
GB9020541D0 (en) Viral growth inhibition
EP0489846A4 (en) Antisense oligonucleotides to c-abl proto-oncogene
ZA907058B (en) Inhibition of deposition in aqueous systems
GB9019611D0 (en) The use of macrolide compounds for cytomegalovirus infection
GB8921133D0 (en) Improved feminine hygiene towel
AU2387292A (en) Antisense oligonucleotides
ZA904825B (en) Inhibition of potato-sprouting
AU7302191A (en) Inhibition of transcription by double-stranded oligonucleotides
NO922169D0 (no) Antisens oligonukleotidinhibisjon av papillomavirus
AU5136693A (en) Antisense oligonucleotides to b myb proto-oncogene
CS667990A3 (en) Agent inhibiting infection power of plant viruses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930215

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

RHK1 Main classification (correction)

Ipc: C12N 15/11

A4 Supplementary search report drawn up and despatched

Effective date: 19930715

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950821

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980303